Home » Newsletters » BioWorld Science

BioWorld Science

July 15, 2022

View Archived Issues

Reduced sensitivity to aspirin by MRP4 may explain ACS risk

miR-411-5p is a predictor of MACE in patients with atrial fibrillation

Chiesi Farmaceutici discloses new ROCK inhibitors

Pandeia Therapeutics patents new GPR88 agonists

GlaxoSmithKline synthesizes new Nav1.8 channel blockers

Zydus Lifesciences identifies new PCSK9 inhibitors

Amgen describes new PRMT5 inhibitors

Characterization of sepsis-induced DIC in murine model

Circulating miRNAs as biomarkers of response to aspirin in patients with high CV risk

D-Dimer confers prognostic value in Kawasaki disease

CM-352 reduces MMP10-driven fibrinolysis in rivaroxaban-associated ICH

To reach their full potential, stem cells need right environment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...